**Company Profile**

**Industry Sector:** Medical Diagnostics

**Company Overview:** Based in Evanston, IL, Ohmx is a clinical diagnostics company developing an accurate, reliable, low-cost, and comprehensive system that quantifies analytes from low-volume biological samples. In addition to developing point-of-care tests (POCT), Ohmx is believed to be developing the only comprehensive platform that can provide analyses of proteins and small molecules at the POC. Ohmx intends to bring to market a large menu of POC tests for screening, monitoring and detection of both acute and chronic diseases.

**Target Market(s):** Major Hospitals and Reference Labs

---

**Management**

**Leadership:**
- Charles Pennington, CEO
- Dr. Fang Lai, VP of R&D
- Dr. Paul Bao, VP of Product Development
- Jorge Castanos, VP of Regulatory and Compliance

**Scientific Advisory Board:**
- Harry B. Gray, Ph.D., California Institute of Technology
- Gary F. Blackburn, Ph.D., Chief Executive Officer of Claremont BioSolutions
- Thomas O'Halloran, Ph.D., Northwestern University
- Holden Thorp, Ph.D., Provost at Washington University in St. Louis
- Richard P. Van Duyne, Ph.D., Northwestern University

---

**Key Value Drivers**

**Technology**: Proteolytic activity assay for Prostate Specific Antigen

**Competitive Advantage:**
- Non-invasive sample collection
- No sample prep required
- Single target
- Simple data analysis
- Fast (mix and read with a plate reader)

**Plan & Strategy:**
Develop a microplate based assay and demonstrate performance characteristics to attract the attention of development partners

---

**Product Pipeline**

1. PPA Test 1 for non-aggressiveness of prostate cancer
2. PPA Test 2 for biochemical recurrence of prostate cancer 2-3 years post surgery